Pharma 4.0 Global Market Rising Trends, Industry Size, Share Report, Growing Demand and Business Opportunities And Forecast 2024-2033 | Alphabet Inc., Pfizer Inc., Cisco Systems Inc., Roche Holding AG, AstraZeneca PLC

The pharma 4.0 market size has grown exponentially in recent years. It will grow from $14.92 billion in 2023 to $17.99 billion in 2024 at a compound annual growth rate (CAGR) of 20.5%. The growth in the historic period can be attributed to regulatory compliance and quality assurance, drug patent expirations and generic competition, increasing healthcare expenditure, demand for personalized medicine and biologics, globalization of pharmaceutical markets.

The pharma 4.0 market size is expected to see exponential growth in the next few years. It will grow to $38.44 billion in 2028 at a compound annual growth rate (CAGR) of 20.9%. The growth in the forecast period can be attributed to shift towards value-based healthcare models, aging population and increased healthcare needs, demand for personalized medicine and precision therapeutics, regulatory reforms and changes in healthcare policies, growing emphasis on patient-centric care and outcomes. Major trends in the forecast period include personalized medicine and precision therapeutics, digital health technologies, value-based healthcare models, regulatory harmonization and accelerated approval processes, supply chain digitization and transparency.

Market Overview -
Pharma 4.0, also known as Pharmaceutical 4.0, refers to the convergence of advanced digital technologies with the pharmaceutical industry, akin to the broader concept of Industry 4.0. It represents a transformative approach to pharmaceutical manufacturing and healthcare delivery, aiming to address rising costs, regulatory compliance, drug shortages, and the need for personalized treatments while unlocking new opportunities for innovation and improving patient care.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=14772&type=smp

Telemedicine And Remote Patient Monitoring Fuel Pharma 4.0 Market Growth
The expansion of telemedicine and remote patient monitoring is expected to propel the growth of the pharma 4.0 market going forward. Telemedicine refers to the practice of providing medical care and consultation remotely using telecommunications technology. Remote patient monitoring involves collecting, transmitting, and analyzing patient health data from a distance using technology-enabled devices and platforms. Telemedicine and remote patient monitoring are expanding due to technological advancements, increasing demand for convenient healthcare access, and the need to manage chronic conditions efficiently. Telemedicine and remote patient monitoring play significant roles in pharma 4.0, facilitating patient-centered care, enabling real-time data collection for personalized medicine, and enhancing pharmaceutical companies' ability to gather patient insights for drug development. For instance, in November 2022, according to Statistics Canada, a Canada-based government agency, one-fourth (24%) of healthcare workers in Canada delivered healthcare services remotely since March 2020, with phone consultations being the most common method, followed by video calls and other digital platforms. Furthermore, in October 2022, according to the Centers for Disease Control and Prevention, a US-based government agency, in the year 2021, telemedicine was utilized by 37.0% of individuals, which increased with age and was more prevalent among women (42.0%) than among men (31.7%). Therefore, the expansion of telemedicine and remote patient monitoring is driving the growth of the pharma 4.0 market.

Competitive Landscape -
Major companies operating in the pharma 4.0 market are Alphabet Inc., Microsoft Corporation, Pfizer Inc., Johnson & Johnson, Amazon Web Services Inc. , Roche Holding AG, International Business Machines Corporation, Merck & Co. Inc., Cisco Systems Inc., Bristol Myers Squibb Company, Oracle Corporation, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Honeywell International Inc., Fujitsu Limited, ABB Ltd., Siemens Healthineers, GE Healthcare, Lotte Corporation, SAS Institute Inc., Optum Inc., POLARISqb, Syntekabio, Optibrium

Adoption Of Cloud-Based Drug Discovery Platforms In Pharma 4.0 Market
Major companies operating in the pharma 4.0 market are developing cloud-based drug discovery platforms, such as StarDrop, to gain a competitive edge. StarDrop is a cloud-based drug discovery platform hosted on remote servers and accessed via the Internet, allowing researchers and pharmaceutical companies to carry out drug discovery activities such as compound screening, molecular modeling, and data analysis in a virtual environment. For instance, in October 2023, Optibrium Ltd., a UK-based biotechnology research company, launched a cloud-based version of its popular drug discovery platform, StarDrop. This platform aims to enhance accessibility and reduce the total cost of ownership for users. It retains all the functionality and interactivity of the desktop application. It allows users to access StarDrop from any internet-connected device, providing greater flexibility for researchers working remotely or across multiple locations. The cloud-based deployment is hosted on Amazon Web Services (AWS). It is supported by Optibrium's ISO 27001-accredited information security system, ensuring advanced data security, including encryption for secure data transfer and protection behind a firewall.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/pharma-4-0-global-market-report

Key Segments -
The pharma 4.0 market covered in this report is segmented -
1) By Component: Hardware, Software, Services
2) By Technology: Cloud Computing, Artificial Intelligence (Al), Big Data Analytics, Internet of Things (IoT)
3) By Application: Drug Discovery And Development, Clinical Trials, Manufacturing
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organizations (CMOs)

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.